Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2010
  • Online publication date: February 2010

Chapter 20 - Metabolic myopathies

from Section 3B - Description of muscle disease – specific diseases

References

1. M. Hirano, S. DiMauro, Metabolic myopathies. Adv. Neurol. 88 (2002), 217–234.
2. S. DiDonato, F. Taroni, Disorders of lipid metabolism. In Myology, Third Edition, eds. A. G. Engel, C. Franzini-Armstrong. (New York: McGraw-Hill, 2004), pp. 1587–1621.
3. B. McArdle, Myopathy due to a defect in muscle glycogen breakdown. Clin. Sci. Lond. 10 (1951), 13–32.
4. J. Kreuder, A. Borkhardt, R. Repp, et al., Inherited metabolic myopathy and hemolysis due to a mutation in aldolase a. N. Engl. J. Med. 334 (1996), 1100–1104.
5. G. P. Comi, F. Fortunato, S. Lucchiari, et al., β-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann. Neurol. 50 (2001), 202–207.
6. G. Kollberg, M. Tulinius, T. Gilljam, et al., Cardiomyopathy and exercise intolerance in muscle glycogen storage disease 0. N. Engl. J. Med. 357 (2007), 1507–1514.
7. J. Vissing, R. G. Haller, A diagnostic cycle test for McArdle's disease. Ann. Neurol. 54 (2003), 539–542.
8. R. G. Haller, J. Vissing, Spontaneous “second wind” and glucose-induced second “second wind” in McArdle disease – oxidative mechanisms. Arch. Neurol. 59 (2002), 1395–1402.
9. R. Quinlivan, J. Vissing, 144th ENMC International Workshop: Outcome Measures in McArdle Disease, 29 September to 1 November 2006, Naarden, the Netherlands. Neuromusc. Disord. 17 (2007), 94–98.
10. R. Aquaron, J. L. Bergé-Lefranc, J. F. Pellissier, et al., Molecular characterization of myophosphorylase deficiency (McArdle disease) in 34 patients from Southern France: identification of 10 new mutations. Absence of genotype-phenotype correlation. Neuromuscul. Disord. 17 (2007), 235–241.
11. S. T. Andersen, M. Dunø, M. Schwartz, J. Vissing, Do carriers of PYGM mutations have symptoms of McArdle disease?Neurology 67 (2006), 716–718.
12. R. M. Quinlivan, R. J. Beynon, Pharmacological and nutritional treatment of McArdle's disease (glycogen storage disease V). Cochrane Database Syst. Rev. 3 (2004), CD003458.
13. J. Vissing, R. G. Haller, The effect of oral sucrose on exercise tolerance in patients with McArdle's disease. N. Engl. J. Med. 349 (2003), 2503–2509.
14. M. C. Ørngreen, H. J. Schelhaas, T. D. Jeppesen, et al., Is muscle glycogenolysis impaired in X-linked phosphorylase b kinase deficiency?Neurology 70 (2008), 1876–1882.
15. S. Tarui, G. Okuno, Y. Ikura, et al., Phosphofructokinase deficiency in skeletal muscle: a new type of glycogenosis. Biochem. Biophys. Res. Commun. 34 (1965), 77–83.
16. R. G. Haller, J. Vissing, No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology 62 (2004), 82–86.
17. R. G. Haller, S. F. Lewis, Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency. N. Engl. J. Med. 324 (1991), 364–369.
18. S. DiMauro, M. Dalakas, A. F. Miranda, Phosphoglycerate kinase deficiency: a new cause of recurrent myoglobinuria. Trans. Am. Neurol. Assoc. 106 (1981), 202–205.
19. S. DiMauro, A. P. Hays, S. Tsujino, Nonlysosomal glycogenoses. In Myology, Third Edition, eds. A. G. Engel, C. Franzini-Armstrong. (New York: McGraw-Hill, 2004), pp. 1535–1558.
20. S. DiMauro, A. F. Miranda, S. Khan, K. Gitlin, R. Friedman, Human muscle phosphoglycerate mutase deficiency: newly discovered metabolic myopathy. Science 212 (1981), 1277–1279.
21. A. Naini, A. Toscano, O. Musumeci, J. Vissing, H. O. Akman, S. DiMauro, Muscle phosphoglycerate mutase (PGAM) deficiency revisited. Arch. Neurol. 66 (2009), 394–398.
22. T. Kanno, K. Sudo, I. Takeuchi, et al., Hereditary deficiency of lactate dehydrogenase M-subunit. Clin. Chim. Acta. 108 (1980), 267–276.
23. G. P. Comi, F. Fortunato, S. Lucchiari, et al., β-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann. Neurol. 50 (2001), 202–207.
24. P. Kazemi-Esfarjani, E. Skomorowska, T. D. Jensen, R. G. Haller, J. Vissing, A nonischemic forearm exercise test for McArdle disease. Ann. Neurol. 52 (2002), 153–159.
25. R. G. Haller, J. Vissing, Functional evaluation of metabolic myopathies. In Myology, Third Edition, eds. A. G. Engel, C. Franzini-Armstrong. (New York: McGraw-Hill, 2004), pp. 665–679.
26. M. Kroos, R. J. Pomponio, L. van Vliet, et al., Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum. Mutat. 29 (2008), E13–E26.
27. M. L. Hagemans, L. P. Winkel, P. A. Van Doorn, et al., Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 128 (2005), 671–677.
28. Pompe Disease Diagnostic Working Group, Methods for a prompt and reliable laboratory diagnosis of Pompe disease: report from an international consensus meeting. Mol. Genet. Metab. 93 (2008), 275–281.
29. J. M. Van den Hout, J. H. Kamphoven, L. P. Winkel, et al., Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113 (2004), e448–457.
30. J. Shen, Y. Bao, H. M. Liu, P. Lee, J. V. Leonard, Y. T. Chen, Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J. Clin. invest. 98 (1996), 352–357.
31. S. W. Moses, R. Parvari, The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies. Curr. Mol. Med. 2 (2002), 177–188.
32. R. Selby, T. E. Starzl, E. Yunis, et al., Liver transplantation for type IV glycogen storage disease. N. Engl. J. Med. 324 (1991), 39–42.
33. D. C. Yao, D. R. Tolan, M. F. Murray, et al., Hemolytic anemia and severe rhabdomyolysis caused by compound heterozygous mutations of the gene for erythrocyte/muscle isozyme of aldolase, ALDOA(Arg303X/Cys338Tyr). Blood 103 (2004), 2401–2403.
34. S. DiMauro, P. Melis-DiMauro, Muscle carnitine palmitoyltransferase deficiency and myoglobinuria. Science 182 (1973), 929–931.
35. N. Gregersen, B. S. Andresen, M. J. Corydon, et al., Mutation analysis in mitochondrial fatty acid oxidation defects: Exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Hum. Mutat. 18 (2001), 169–189.
36. K. Bartlett, S. Eaton, Mitochondrial beta-oxidation. Eur. J. Biochem. 271 (2004), 462–469.
37. N. Longo, C. Amat di San Filippo, M. Pasquali, Disorders of carnitine transport and the carnitine cycle. Am. J. Med. Genet. C. Semin. Med. Genet. 142 (2006), 77–85.
38. Y. Wang, F. Taroni, B. Garavaglia, N. Longo, Functional analysis of mutations in the OCTN2 transporter causing primary carnitine deficiency: lack of genotype-phenotype correlation. Hum. Mutat. 16 (2000), 401–407.
39. J. P. Bonnefont, F. Djouadi, C. Prip-Buus, S. Gobin, A. Munnich, J. Bastin, Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol. Aspects Med. 25 (2004), 495–520.
40. M. Deschauer, F. Taroni, Carnitine palmitoytransferase II deficiency. In MedLink Neurology, ed. S. Gilman. (San Diego, CA: MedLink Corporation, 2006), available at www.Medlink.com
41. J. M. Saudubray, D. Martin, P. de Lonlay, et al., Recognition and management of fatty acid oxidation defects: a series of 107 patients. J. Inherit. Metab. Dis. 22 (1999), 488–502.
42. C. Angelini, A. Federico, H. Reichmann, A. Lombes, P. Chinnery, D. Turnbull, Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur. J. Neurol. 13 (2006), 923–929.
43. P. J. Isackson, M. J. Bennett, G. D. Vladutiu, Identification of 16 new disease-causing mutations in the CPT2 gene resulting in carnitine palmitoyltransferase II deficiency. Mol. Genet. Metab. 89 (2006), 323–331.
44. F. Taroni, E. Verderio, F. Dworzak, P. J. Willems, P. Cavadini, S. DiDonato, Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients. Nat. Genet. 4 (1993), 314–320.
45. M. C. Orngreen, R. Ejstrup, J. Vissing, Effect of diet on exercise tolerance in carnitine palmitoyltransferase II deficiency. Neurology 61 (2003), 559–561.
46. R. Pons, P. Cavadini, S. Baratta, et al., Clinical and molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency. Pediatr. Neurol. 22 (2000), 98–105.
47. M. C. Orngreen, M. G. Norgaard, B. G. van Engelen, B. Vistisen, J. Vissing, Effects of IV glucose and oral medium-chain triglyceride in patients with VLCAD deficiency. Neurology 69 (2007), 313–315.
48. S. E. Olpin, S. Clark, B. S. Andresen, et al., Biochemical, clinical and molecular findings in LCHAD and general mitochondrial trifunctional protein deficiency. J. Inherit. Metab. Dis. 28 (2005), 533–544.
49. M. B. Gillingham, W. E. Connor, D. Matern, et al., Optimal dietary therapy of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. Mol. Genet. Metab. 79 (2003), 114–123.
50. C. O. Harding, M. B. Gillingham, S. C. van Calcar, J. A. Wolff, J. N. Verhoeve, M. D. Mills, Docosahexaenoic acid and retinal function in children with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. J. Inherit. Metab. Dis. 22 (1999), 276–280.
51. I. Tein, J. Vajsar, L. MacMillan, W. G. Sherwood, Long-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency neuropathy: response to cod liver oil. Neurology 52 (1999), 640–643.
52. C. Antozzi, B. Garavaglia, M. Mora, et al., Late-onset riboflavin-responsive myopathy with combined multiple acyl coenzyme A dehydrogenase and respiratory chain deficiency. Neurology 44 (1994), 2153–2158.
53. R. K. Olsen, S. E. Olpin, B. S. Andresen, et al., ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain 130 (2007), 2045–2054.
54. K. Gempel, H. Topaloglu, B. Talim, et al., The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 130 (2007), 2037–2044.
55. P. Rinaldo, D. Matern, M. J. Bennett, Fatty acid oxidation disorders. Annu. Rev. Physiol. 64 (2002), 477–502.
56. M. He, S. L. Rutledge, D. R. Kelly, et al., A new genetic disorder in mitochondrial fatty acid beta-oxidation: ACAD9 deficiency. Am. J. Hum. Genet. 81 (2007), 87–103.
57. K. G. Sim, J. Hammond, B. Wilcken, Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders. Clin. Chim. Acta. 323 (2002), 37–58.
58. M. J. Bennett, Assays of fatty acid beta-oxidation activity. Methods Cell. Biol. 80 (2007), 179–197.
59. N. Gregersen, B. S. Andresen, P. Bross, Prevalent mutations in fatty acid oxidation disorders: diagnostic considerations. Eur. J. Pediatr. 159 (2000), S213–S218.
60. P. Rinaldo, A. L. Studinski, D. Matern, Prenatal diagnosis of disorders of fatty acid transport and mitochondrial oxidation. Prenat. Diagn. 21 (2001), 52–54.
61. R. Pons, D. C. De Vivo, Mitochondrial disease. Curr. Treat. Options Neurol. 3 (2001), 271–288.
62. M. B. Gillingham, B. Scott, D. Elliott, C. O. Harding, Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol. Genet. Metab. 89 (2006), 58–63.
63. C. R. Raoe, L. Sweetman, D. S. Roe, F. David, H. Brunengraber, Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J. Clin. Invest. 110 (2002), 259–269.
64. S. Gobin-Limballe, F. Djouadi, F. Aubey, et al., Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Am. J. Hum. Genet. 81 (2007), 1133–1143.
65. S. Primassin, F. Ter Veld, E. Mayatepek, U. Spiekerkoetter, Carnitine supplementation induces acylcarnitine production in tissues of very long-chain acyl-CoA dehydrogenase-deficient mice, without replenishing low free carnitine. Pediatr. Res. 63 (2008), 632–637.